Abstract
A novel binding site for the adenosine receptor agonist 5′-N-ethylcarboxamidoadenosine (NECA), which was enriched in rat forebrain, was characterized in cytosolic and particulate preparations. The site showed a pharmacological profile different from other [ 3H]NECA binding proteins and was named adenotin 2. [ 3H]NECA was; bound in the presence of 100 μM 2-chloroadenosine with a K d of 45.4 nM and a B max of 4711 fmol/mg in the cytosol and a K d of 72.4 nM and a B max of 4844 fmol/mg in the crude membrane fraction. The presence of two different binding sites on adenotin 2 for [ 3H]NECA was shown in kinetic experiments. This protein showed identical pharmacological profiles in both subcellular preparations. [ 3H]NECA was displaced by purine analogues with a rank order of potency of NECA > 3′5′ cyclic AMP (cAMP) > 5′-deoxy-5′-chloroadenosine > S-adenosylhomocysteine ≈ 5′-deoxy-5′-methylthioadenosine (MeSA) > adenosine ≈ adenine. cAMP inhibited [ 3H]NECA binding allosterically, whereas adenine and MeSA acted competitively. Inhibitors and activators of protein kinases such as N-(2-aminoethyl)-5-isoquinolinesulfonamide, Sp-adenosine cyclic monophophothioate and (8R ∗, 9S ∗, 11S ∗)-(−)−9-hydroxy-9-methoxy-carbonyl-8-methyl-2,3,9,10-tetrahydro-8, 11-epoxy-lH, 8H, 11H-2, 7b, lla-triazadibenzo-(a,g)cycloocta(cde)-trinden-1-one (K 252a) interacted with [ 3H]NECA binding to adenotin 2 in nanomolar concentrations. Adenosine-5′-O-(3-thiotriphosphate] (100 μM) increased the affinity of [ 3H]NECA to a K d of 9 nM and diminished the affinity of cAMP. The pharmacological characteristics of this novel binding site for [ 3H]NECA resemble those of the inhibition of phosphorylation processes by adenosine and its derivatives in heart and smooth muscle but are distinct from known adenosine receptors, adenosine binding proteins and protein kinases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.